CompletedPhase 4

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

United States35 participantsStarted 2017-07-10

Plain-language summary

This study evaluates the possible acute changes in peripapillary blood flow after instillation of antiglaucoma medications in patients with primary open angle glaucoma (POAG), normal tension glaucoma (NTG), or ocular hypertension (OHTN) using Optical Coherence Tomography (OCT) angiography.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of ocular hypertension, primary open angle glaucoma, or normal tension glaucoma in the study eye(s) * Age 18-90 * Best corrected visual acuity of 20/60 or better Exclusion Criteria: * Current use of either brimonidine or timolol * Other disease, ophthalmic or systemic, that is likely to significantly affect the OCT test in the study eye(s) including: * More than moderate grade cataract that significantly reducing OCTA scan signal level * Macular degeneration other than mild drusen or pigmentary changes * Diabetic retinopathy other than mild background non proliferative retinopathy * Prior or current macular edema * Prior laser treatment to the retina * Prior retinal detachment * Prior central serous retinopathy * Prior retinal vein or artery occlusion * Prior inflammatory retinopathy or choroidopathy * Keratoconus or other corneal ectasia * Corneal scarring in central 4 mm * Prior penetrating keratoplasty * Ischemic optic neuropathy * Dementia beyond early/mild memory loss * History of cerebrovascular accident * History of severe carotid stenosis * History of previous ocular surgery other than non-complicated cataract extraction

What they're measuring

Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography

Timeframe: 5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)

Changes in Flow Index in Treatment Groups Assessed by OCT Angiography

Timeframe: 5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)

Comparison of Percent Changes in Peripapillary Vessel Density in Treatment Groups Assessed by OCT Angiography

Timeframe: 5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)

Comparison of Percent Changes in Peripapillary Flow Index in Treatment Groups Assessed by OCT Angiography

Timeframe: 5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)

Comparison of Percent Changes in Optic Nerve Head Vessel Density in Treatment Groups Assessed by OCT Angiography

Timeframe: 5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)

Comparison of Percent Changes in Optic Nerve Head Flow Index in Treatment Groups Assessed by OCT Angiography

Timeframe: 5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)

Trial details

NCT IDNCT03323164

SponsorWills Eye

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12-31

Results submitted2020-08-20

View on ClinicalTrials.gov More Glaucoma; Drugs trials